RYMAN HEALTHCARE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 NZD | +2.34% |
|
-1.13% | -40.68% |
| Jun. 27 | Ryman Healthcare Chooses PwC Auckland as External Auditor | MT |
| May. 27 | Transcript : Ryman Healthcare Limited, 2024 Earnings Call, May 27, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 5.76 and 6.64 for the ongoing fiscal year and 2026 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is not the most generous with respect to shareholders' compensation.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -40.68% | 1.47B | B | ||
| +16.82% | 82.82B | C+ | ||
| -27.95% | 71.42B | B- | ||
| -0.35% | 26.41B | C+ | ||
| +3.49% | 17.73B | A- | ||
| -10.70% | 17.11B | B | ||
| +0.75% | 15.43B | A- | ||
| +74.84% | 13.45B | C- | ||
| -25.44% | 12.86B | - | - | |
| +71.06% | 12.63B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RYM Stock
- Ratings Ryman Healthcare Limited
